New trials, publications, preprints and grants on this target, month by month.
Trial
Prospective Study to Evaluate the Clinical Utility of ctDNA Tumor Fraction (TF) for Detection of Estrogen Receptor 1 (ESR1) Mutations in (Human Epidermal Growth Factor Receptor) HR+/HER2- Metastatic Breast Cancer (MBC)
1 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor.
31 Oct 2026· Future oncology (London, England)· PUBMED
Publication
Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer.
13 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Development of a clinical-grade ultrasensitive droplet digital PCR test for monitoring of relevant ESR1 variants by liquid biopsy.
13 Oct 2026· The journal of liquid biopsy· PUBMED
Publication
Hyodeoxycholic acid rejuvenates BMSCs against postmenopausal osteoporosis by attenuating senescence and aberrant adipogenesis via TGR5-ESR1-mediated mitophagy.
10 Oct 2026· Journal of advanced research· PUBMED
Publication
AMCP Market Insights: Managed care approaches to ESR1-mutated advanced breast cancer.
1 Oct 2026· Journal of managed care & specialty pharmacy· PUBMED
Publication
Identification and Validation of the ESR1 Y537S Mutant-Enriched Enhancer and Its Downstream Target IGFBP3.
1 Oct 2026· Cancer research communications· PUBMED
Trial
SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC
30 Sept 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
FDA adds vepdegestrant to options for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer.
15 Sept 2026· Cancer· PUBMED
Publication
Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting.
14 Sept 2026· ESMO open· PUBMED
Publication
Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018-2024.
9 Sept 2026· Breast cancer research and treatment· PUBMED
Publication
Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024.
9 Sept 2026· Breast cancer research and treatment· PUBMED
Publication
Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2- Metastatic Breast Cancer.
8 Sept 2026· Molecular diagnosis & therapy· PUBMED
Trial
A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
18 Aug 2026· PHASE2 · RECRUITING· CTGOV
Preprint
Extreme ESR1 Polyclonality, Mutation Dynamics, and Effects on Treatment Outcomes in Patients with ER+ Metastatic Breast Cancer.
10 Aug 2026· Research square· PUBMED
Publication
Correlation between ESR1 mutation and PD-L1 expression in breast carcinoma: A narrative review.
1 Aug 2026· Critical reviews in oncology/hematology· PUBMED
Publication
Dynamic circulating tumor DNA profiling of ESR1 mutations in HR+/HER2- advanced breast cancer: from prognostic biomarker to clinical decision-making - a comprehensive review.
31 Jul 2026· Frontiers in oncology· PUBMED
Publication
ESR1 Y537S Detected in a Brain Metastasis but Not in Plasma ctDNA in HR+/HER2-Low Metastatic Breast Cancer: A Case Report.
28 Jul 2026· Current oncology (Toronto, Ont.)· PUBMED
Publication
ESR1-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6.
23 Jul 2026· Journal of immunotherapy and precision oncology· PUBMED
Publication
Pharmacologic targeting of midasin (MDN1) reveals a potential therapeutic vulnerability in ESR1-mutant breast cancer.
17 Jul 2026· Frontiers in pharmacology· PUBMED
Publication
[Imlunestrant - ER+/HER2-, locally advanced or metastatic breast cancer with an activating ESR1 mutation].
15 Jul 2026· Bulletin du cancer· PUBMED
Publication
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
13 Jul 2026· The Lancet. Oncology· PUBMED
Publication
Cancer-related microangiopathic hemolytic anemia (CR-MAHA) in a metastatic breast cancer patient with a germ-line ATM single nucleotide variant and an ESR1 fusion variant: insights from a case report on early diagnosis and improved outcomes.
7 Jul 2026· Frontiers in oncology· PUBMED
Publication
Endothelial estrogen receptor alpha (ESR1) regulates cerebral cavernous malformation pathogenesis via MEKK3-KLF signaling pathway.
6 Jul 2026· Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism· PUBMED
Publication
ESR1 and PIK3CA circulating tumor DNA (ctDNA) mutation status as predictive biomarkers beyond variant allele fraction (VAF) in metastatic breast cancer.
3 Jul 2026· The journal of liquid biopsy· PUBMED
Publication
ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance.
27 Jun 2026· Genome medicine· PUBMED
Publication
The ESR1-MYH14 axis functions as a critical driver of cervical cancer progression and metastasis.
25 Jun 2026· Translational oncology· PUBMED
Publication
A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with ESR1-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine Therapy.
24 Jun 2026· Cancers· PUBMED
Trial
Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
19 Jun 2026· NA · RECRUITING· CTGOV
Publication
A Plant-Derived Flavonoid, Isobavachin, Promotes Osteogenesis and Alleviates Glucocorticoid-Induced Osteoporosis via Modulation of the ESR1-PI3K/Akt Signaling Pathway.
18 Jun 2026· Molecules (Basel, Switzerland)· PUBMED